Health Care • Biotechnology: Pharmaceutical Preparations
$317.33 ▼ -1.45
(-0.45%)
MKT CAP: $6.33B • VOL: 299.5K
52W L $176 52W H $327
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$267
MEDIAN
$355
MEAN
$362
HIGH
$432
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LGND TAPE
LGND // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $383.97 | $364.93 | 2025-02-14 | $288.77 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $399.84 | $374.45 | 2025-02-06 | $298.29 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $361.76 | $349.06 | 2025-01-29 | $304.64 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $323.68 | — | 2025-01-17 | $310.98 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $279.25 | $301.46 | 2025-01-09 | $282.42 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $377.62 | $330.02 | 2024-12-18 | $276.08 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $307.81 | $320.50 | 2024-12-04 | $295.12 | -4.3% | 48% | C |